Financials
- Market Capitalization 1.79 B
- Employee 110
- Founded 2024
- CEO N/A
- Website www.inhibrx.com
- Headquarter Delaware, United States
- FIGI BBG01MS5Q9G3
- Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-10.67
ratio cours/chiffre d'affaires
—
Related tickers
| # | Nom | Prix | 24h % | 7 jours % | 1M % | 1 an % | Cap Boursière | 7 Derniers Jours | |
|---|---|---|---|---|---|---|---|---|---|
| 2041 | TSHA Taysha Gene Therapies, Inc. - Common Stock | 5.72 USD | +0.53% | -7.89% | -2.89% | +97.24% | 1.86 B USD | ||
| 2064 | RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock | 3.36 USD | -1.18% | -4.55% | +10.89% | -26.80% | 1.80 B USD | ||
| 2070 | SEPN Septerna, Inc. - Common Stock | 38.27 USD | +0.31% | -5.83% | +11.09% | +73.88% | 1.79 B USD | ||
| 2075 | NTLA Intellia Therapeutics, Inc. - Common Stock | 12.76 USD | +0.24% | -5.20% | +20.49% | -7.00% | 1.79 B USD |